1Associate of prod.,Departmaent of Genetics,IAU,Tehran medical branch
2Department of Biology, Science and research branch, Islamic Azad University, Tehran, IRAN
3Department of Biology, Faculty of Science, Shahed University, Tehran, IRAN
Recently, specific attention has been paid to aptamers, short DNA or RNA, as a tool for cancer diagnosis and therapy. In the present study MCS nanogels were prepared by Myristate: chitosan at 1:9 ratio and were characterized by several techniques. A selected ssDNA aptamer(Apt) capable of detecting LNCaP cells was linked to Myristilated chitosan nanogels (Apt-MCS) by glutaraldehyde and loaded with Doxorubicin (DOX) to be used in targeted drug delivery against the Prostate cancer cells. LNCaP and PC-3 cells were treated with Apt-MCS-DOX complex and the binding efficiency was estimated by flow cytometry. The binding affinity of the selected aptamers was above 70% compared to the initial library. The loading capacity of the nanogel was as high as 97% and up to 40% of DOX were released from MCS within 15 days.Cytotoxicity of nanodrugs on LNCaP cells were determined by MTT assay. Apt-MCS-DOX was specifically binded to LNCaP cells whereas it didn’t show any specificity to PC-3 cells as a negative control. Both MCS-DOX and Apt-MCS-DOX showed a lethal effect on LNCaP cells. Our results can lead to an aptamer based simple and applicable technique for early diagnosis and treatment of cancerous cells. Keywords: DOX; MCS; nanogel; aptamer; Targeted drug delivery; Prostate cancer.